Research Article
Prognostic Analysis of Duodenal Gastrointestinal Stromal Tumors
Table 1
Clinical and pathological features for 55 cases of DGIST associate with disease-free survival (DFS) and overall-survival (OS).
| Characteristic | N (%) | DFS (month) | Chi-square value | value | OS (month) | Chi-square value | value |
| Gender | | | 3.383 | 0.066 | | 3.451 | 0.063 | Male | 26 (47.27) | 101.7 ± 10.91 | | | 122.5 ± 11.10 | | | Female | 29 (52.73) | 137.4 ± 9.292 | | | 147.3 ± 7.249 | | | Age | | | 0.584 | 0.445 | | 0.047 | 0.829 | ≥60 | 15 (27.27) | 132.2 ± 12.26 | | | 130.3 ± 12.91 | | | <60 | 40 (72.73) | 120.8 ± 9.744 | | | 138.3 ± 7.716 | | | Symptoms | | | 0.01 | 0.921 | | 0.35 | 0.554 | Asymptomatic | 6 (10.91) | | | | | | | Abdominal pain/distention | 17 (30.91) | | | | | | | Hemorrhage/anemia | 31 (56.36) | | | | | | | Abdominal mass | 1 (1.82) | | | | | | | Surgical method | | | 2.16 | 0.142 | | 1.308 | 0.253 | Whipple/child | 18 (32.73) | 63.30 ± 6.771 | | | 73.58 ± 4.941 | | | Local resection | 37 (67.27) | 131.6 ± 8.522 | | | 140.0 ± 6.8 | | | Growth pattern | | | 2.637 | 0.268 | | 0.62 | 0.733 | Exophytic growth | 37 (67.3) | 121.7 ± 7.185 | | | 123.2 ± 8.342 | | | Intraluminal growth | 10 (18.2) | 94.14 ± 19.40 | | | 144.0 ± 8.981 | | | Both | 8 (14.5) | 116.8 ± 21.05 | | | 117.8 ± 20.39 | | | Tumor size | | | 4.281 | 0.039 | | 4.867 | 0.027 | ≤5 cm | 17 (30.91) | 135.1 ± 8.105 | | | 144.4 ± 6.695 | | | >5 cm | 38 (69.09) | 101.9 ± 15.67 | | | 112.7 ± 16.32 | | | Tumor size | | | 0.003 | 0.958 | | 0.039 | 0.844 | ≤2 cm | 9 (16.36) | 121.8 ± 14.76 | | | 132.7 ± 4.355 | | | 2~5 cm | 29 (52.73) | 135.4 ± 8.946 | | | 146.1 ± 8.200 | | | Site | | | 2.548 | 0.467 | | 2.496 | 0.476 | Bulb | 6 (10.91) | | | | | | | Descending | 27 (49.09) | | | | | | | Horizontal | 21 (38.18) | | | | | | | Ascending | 1 (1.818) | | | | | | | Mitotic activity | | | 14.25 | 0.001 | | 10.05 | 0.007 | <5/50 HPF | 40 (72.73) | 123.3 ± 9.080 | | | 144.4 ± 6.695 | | | 5~10/50 HPF | 9 (16.36) | 103.4 ± 17.88 | | | 121.5 ± 18.29 | | | >10/50 HPF | 6 (10.91) | 40.29 ± 6.047 | | | 59.60 ± 10.65 | | | Ki-67 index | | | 26.21 | <0.001 | | 12.92 | <0.001 | ≤5% | 38 (69.09) | 147.3 ± 5.136 | | | 151.5 ± 3.492 | | | >5% | 17 (30.91) | 43.88 ± 6.000 | | | 92.53 ± 12.63 | | | Pathological risk | | | 25.28 | 0.005 | | 11 | 0.012 | Very low | 9 (16.36) | | | | | | | Low | 24 (43.64) | | | | | | | Intermediate | 9 (16.36) | | | | | | | High | 13 (23.64) | | | | | | | Imatinib after surgery for middle-high pathological risk | | | 0.478 | 0.489 | | 0.062 | 0.804 | Yes | 6 (27.27) | 41.17 ± 7.531 | | | 58.00 ± 11.43 | | | No | 16 (72.73) | 111.3 ± 14.79 | | | 122.7 ± 14.55 | | | Imatinib after recurrence | | | | | | 9.811 | 0.002 | Yes | 6 (54.55) | | | | 125.6 ± 12.16 | | | No | 5 (45.45) | | | | 35.73 ± 12.71 | | |
|
|